Clinical Trial Update: Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for Fuzhenghuayu in patients with primary biliary cholangitis who did not respond adequately to ursodeoxycholic acid.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Fuzhenghuayu (Fuzhenghuayu)

Snippet

Sponsor: Xijing Hospital of Digestive Diseases | Conditions: Primary Biliary Cirrhosis | Phase 3 | Status: UNKNOWN